Nutritional adequacy requires attention, as very-low-carbohydrate diets restrict many nutrient-dense foods including fruits, whole grains, and legumes
In the STEP UP T2D trial, more than 500 patients with obesity and type 2 diabetes were treated during the same period of time
Beyond glycemic control, GLP-1 receptor agonists act on appetite centers in the brain, particularly the hypothalamus, reducing hunger signals and promoting feelings of fullness
In an era where healthcare can feel impersonal and prohibitively expensive, it is natural to look for alternatives
These will be discussed in detail below in Clinical uses
What New Research Suggests Key Takeaways GLP-1 medications are established treatments for diabetes and obesity